Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vitamin D binding protein macrophage-activating factor - Efranat

Drug Profile

Vitamin D binding protein macrophage-activating factor - Efranat

Alternative Names: EF-022; GcMAF; Globulin component macrophage activating factor

Latest Information Update: 11 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Einstein Medical Center
  • Developer Efranat; Socrates Institute for Therapeutic Immunology
  • Class Antineoplastics; Carrier proteins; Lymphokines
  • Mechanism of Action Macrophage activating factor replacements; Macrophage stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Recurrent respiratory papillomatosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Recurrent respiratory papillomatosis
  • Discontinued Breast cancer; Colorectal cancer; Prostate cancer

Most Recent Events

  • 11 Dec 2017 Phase I development for Solid tumours is ongoing in Israel (Efranat pipeline, December 2017)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Metastatic disease, Recurrent) in Israel (IM, Injection)
  • 27 Jun 2017 Discontinued - Phase-I for Breast cancer (Metastatic disease) in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top